OncoMatch/Clinical Trials/NCT06158139

Autologous CAR-T Cells Targeting B7-H3 in PDAC

Is NCT06158139 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies iC9-CAR.B7-H3 T cell infusion for pancreas cancer.

Phase 1RecruitingUNC Lineberger Comprehensive Cancer CenterNCT06158139Data as of May 2026

Treatment: iC9-CAR.B7-H3 T cell infusion — The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9.CAR.B7-H3 T cells) in patients with pancreatic ductal adenocarcinoma that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify